Research and experimental development on natural sciences and engineering
BIONOR IMMUNO AS
Operating profit
NOK −93,000
Equity
NOK −17.1m
Incorporated
2000
Share capital
NOK 984,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating costs | 93k | |
| Operating profit (EBIT) | −93k | |
| Net financial items | −75k | |
| Profit for the year | −167k |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 138k | |
| of which current assets | 138k | |
| Equity | −17.1m | |
| Total liabilities | 17.3m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.